Corneal Pharmacokinetics of Voriconazole and Posaconazole following Intrastromal Injection and Posaconazole Eye Drops Instillation in Rats

ABSTRACT Purpose/Aims: Infectious keratitis is a major cause of visual impairment and blindness worldwide. Common difficulties in treating fungal keratitis prompt new therapeutic possibilities. In this study, intrastromal voriconazole and posaconazole, and topical posaconazole were tested for their potential to obtain therapeutic cornea concentrations. Materials and Methods: Pharmacokinetics of triazole intracorneal/eye drop administration was studied in rats. Sixty-two rats were treated either by voriconazole or posaconazole. Twenty-nine and 33 rats received intrastromal injection of voriconazole solution (1 μl, 10 mg/ml) and posaconazole solution (1 μl, 18 mg/ml), respectively, administered under microscopic examination with a 32 gauge needle in the left cornea. Posaconazole (1.8% solution) eye drops were used. Cornea and plasma concentrations were determined using 2D HPLC separation and tandem MS, at 30 min, 3 h, 6 h, 24 h, 48 h, 72 h, and 144 h (6 days) post-intrastromal injection. The entire rat cornea was used for chromatography analyses. Results: In anesthetized rats, single intracorneal injection resulted, after 30 min, in respectively, >300 ng/mg and >260 ng/mg cornea concentrations, dropping to low levels within hours, while staying low in plasma. The effect of hourly posaconazole eye drops resulted in >10 ng/mg cornea concentration, which was maintained with instillations every 2 and then every 4 h. Conclusion: Our results show that there is little interest of intrastromal triazole administration due to the short duration of high cornea concentrations obtained after intracorneal injection. Posaconazole eye drops maintain therapeutic cornea concentrations in rats and could be used to treat severe infectious keratitis.

[1]  J. Rose-Nussbaumer,et al.  Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole. , 2019, Ophthalmology.

[2]  H. Yamaguchi,et al.  Efficacy of Luliconazole Against Broad-Range Filamentous Fungi Including Fusarium solani Species Complex Causing Fungal Keratitis , 2018, Cornea.

[3]  G. Satpathy,et al.  Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol , 2018, Cornea.

[4]  J. Ballet,et al.  Evaluation of voriconazole anti-Acanthamoeba polyphaga in vitro activity, rat cornea penetration and efficacy against experimental rat Acanthamoeba keratitis , 2018, The Journal of antimicrobial chemotherapy.

[5]  S. Ranque,et al.  Current antifungal treatment of fusariosis. , 2017, International journal of antimicrobial agents.

[6]  J. Rose-Nussbaumer,et al.  Update on the Management of Infectious Keratitis. , 2017, Ophthalmology.

[7]  C. Girmenia,et al.  An update on the safety and interactions of antifungal drugs in stem cell transplant recipients , 2017, Expert opinion on drug safety.

[8]  S. V. van Hal,et al.  Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. , 2016, International journal of antimicrobial agents.

[9]  L. Thiberville,et al.  Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. , 2016, International journal of antimicrobial agents.

[10]  H. Waskin,et al.  Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease , 2014, Antimicrobial Agents and Chemotherapy.

[11]  Ling-hui Qu,et al.  Toxicity and Pharmacokinetics of Intrastromal Injection of Amphotericin B in a Rabbit Model , 2014, Current eye research.

[12]  G. Satpathy,et al.  Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. , 2013, Ophthalmology.

[13]  E. Edell,et al.  Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. , 2010, American journal of ophthalmology.

[14]  Ling-hui Qu,et al.  Corneal and Aqueous Humor Concentrations of Amphotericin B Using Three Different Routes of Administration in a Rabbit Model , 2009, Ophthalmic Research.

[15]  Russell N Van Gelder,et al.  Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. , 2008, Archives of ophthalmology.

[16]  Jennifer L Davis,et al.  Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. , 2006, American journal of veterinary research.

[17]  W. Sponsel,et al.  Topical Voriconazole as a Novel Treatment for Fungal Keratitis , 2006, Antimicrobial Agents and Chemotherapy.

[18]  E. Garcia-Valenzuela,et al.  Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. , 2005, Archives of ophthalmology.

[19]  L. Polonelli,et al.  Voriconazole activity against clinical yeast isolates: a multicentre Italian study. , 2005, International journal of antimicrobial agents.

[20]  I. Avni,et al.  Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin , 2003, The British journal of ophthalmology.

[21]  W. Sponsel,et al.  Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis , 2002, The British journal of ophthalmology.

[22]  M. Pfaller,et al.  Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000 , 2002, Antimicrobial Agents and Chemotherapy.

[23]  H. Yamaguchi,et al.  In vitro antifungal activity of posaconazole against various pathogenic fungi. , 2001, International journal of antimicrobial agents.